Brinex is a drug used in ophthalmology. It is an antiglaucoma drug and a miotic.
Brinex is indicated for the reduction of elevated intraocular pressure in ocular hypertension; open-angle glaucoma; as monotherapy for adult patients insensitive to beta-blockers or for adult patients for whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.
Warehouse
1 ml of suspension contains 10 mg of brinzolamide; excipients: benzalkonium chloride, sodium chloride, disodium edetate, carbomer 974P, mannitol (E 421), tyloxapol, sodium hydroxide, hydrochloric acid, water for injections.
Contraindication
Hypersensitivity to the active substance or to any other component of the drug; hypersensitivity to sulfonamides; severe renal failure; hyperchloremic acidosis.
Method of application
When using Brinex as monotherapy or adjunctive therapy, the dose is 1 drop in the conjunctival sac of the affected eye 2 times a day. Some patients may achieve better results with 1 drop 3 times a day.
If another ophthalmic antiglaucoma agent is substituted for Brinex, the other agent should be discontinued and Brinex should be started the next day.
If more than one topical ophthalmic agent is used, the interval between their applications should be at least 5 minutes. Eye ointments should be applied last.
If a dose is missed, treatment should be continued with the next dose according to the treatment regimen. The dose should not exceed 1 drop in the affected eye 3 times a day.
Application features
Brinzolamide, a carbonic anhydrase inhibitor, is a sulfonamide derivative and is systemically absorbed when applied topically. Therefore, topical application of brinzolamide may result in adverse reactions typical of sulfonamides. If serious adverse reactions or hypersensitivity reactions occur, the drug should be discontinued.
Acid-base disturbances have been reported with oral carbonic anhydrase inhibitors. As there is a risk of metabolic acidosis, the drug should be used with caution in patients at risk of renal impairment.
Oral carbonic anhydrase inhibitors may impair the ability to perform tasks requiring mental alertness and/or physical coordination in elderly patients. Since Brinex is absorbed systemically, such effects may also occur with topical administration.
Pregnant women
There are no data on the use of brinzolamide in pregnant women. Brinex should not be administered to pregnant women or women of childbearing potential not using contraception.
Children
Brinex is not used in children under 18 years of age.
Drivers
There are no data on the use of brinzolamide in pregnant women. Brinex should not be administered to pregnant women or women of childbearing potential not using contraception.
Overdose
No cases of overdose have been reported.
In case of overdose, treatment should be symptomatic and supportive. Electrolyte imbalance, acidosis and possible nervous system effects may occur. Serum electrolyte levels (especially potassium) and blood pH should be monitored.
Side effects
Infectious and parasitic diseases: rhinopharyngitis, pharyngitis, sinusitis, rhinitis.
Blood and lymphatic system disorders: decreased red blood cell count, increased blood chloride levels.
Immune system disorders: hypersensitivity.
Mental disorders: apathy, depression, depressed mood, decreased libido, nightmares, insomnia, nervousness.
Metabolic disorders: decreased appetite.
Storage conditions
Store at a temperature not exceeding 30°C in the original packaging. Do not freeze.
Keep out of reach of children.
